Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
+$0.02 today
- Market cap
- $546.27M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
Volume 0.87M
Average 0.88M
CLYM Total Non-current Liabilities
All obligations due after more than one year.
Climb Bio, Inc.NASDAQ: CLYM
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 32.3% from a year ago
Total non-current liabilities stood at $216K at the end of Q1 FY2026, down 32.3% from a year earlier and down 24.2% from the prior quarter. Over 3 fiscal years it compounded at +16.6% a year.
Context
- Total non-current liabilities amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -32.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 285K USD
- Year-over-year change
- -24.0%
- 4-year CAGR
- +152.6%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 285K | -24.0% |
| FY2024 | 2024-12-31 | 375K | +913.5% |
| FY2023 | 2023-12-31 | 37K | -79.4% |
| FY2022 | 2022-12-31 | 180K | +2471.4% |
| FY2021 | 2021-12-31 | 7K | — |
Total Non-current Liabilities vs competitors
How CLYM compares with its peers on the latest reported figures
- CLYM's Mar 2026 total non-current liabilities of $216K is the 4th highest of the 5 companies compared; the peer median is $1.86M.
- Its year-over-year change of -32.3% is the 3rd highest of 5, against a peer median of -36.7%.
- Total non-current liabilities amounts to 0.1% of total assets for CLYM, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $32.75M | -12.8% | +219.4% | 22.3% | |
| Mar 2026 | $3.33M | -65.3% | -0.9% | 2.3% | |
UPBUpstream Bio, Inc. | Mar 2026 | $390K | -60.7% | -83.4% | 0.1% |
CLYMClimb Bio, Inc. | Mar 2026 | $216K | -32.3% | +16.6% | 0.1% |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | +100.0% | — | 0.0% |
| Peer median (excluding CLYM) | $1.86M | -36.7% | -0.9% | 1.2% | |
Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 46.92M | 43.59M | 93.11M | 87.23M | 35.69M |
| Short-term Investments | 89.56M | 79.98M | 13.69M | 63.69M | 65.39M |
| Net Receivables | 6.52M | 6.49M | 2.46M | 1.12M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 852K | 3.01M | 112K | 256K | 4.77M |
| Total Current Assets | 148.25M | 134.39M | 110.26M | 154.87M | 105.85M |
| Property, Plant & Equipment (Net) | 0 | 471K | 199K | 490K | 793K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 24.92M | 0 | 0 | 61.61M | 59.57M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 70K | 128K | 15K | 215K | 1.53M |
| Total Non-current Assets | 24.99M | 599K | 214K | 62.32M | 61.89M |
| Total Assets | 173.24M | 134.99M | 110.47M | 217.19M | 167.74M |
| Account Payables | 1.4M | 750K | 66K | 705K | 2.27M |
| Short-term Debt | 0 | 0 | 0 | 0 | 256K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 138K | 31K | 2.57M |
| Total Current Liabilities | 6.03M | 6.1M | 2.83M | 4.93M | 6.98M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7K | 0 | 22K | 0 | 0 |
| Total Non-current Liabilities | 7K | 180K | 37K | 375K | 285K |
| Total Liabilities | 6.04M | 6.28M | 2.87M | 5.31M | 7.27M |
| Common Stock | 3K | 3K | 3K | 7K | 5K |
| Retained Earnings | (75.62M) | (120.86M) | (155.98M) | (229.88M) | (289.73M) |
| Accumulated OCI | (123K) | (358K) | (2K) | 23K | 435K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 167.2M | 128.72M | 107.6M | 211.88M | 160.48M |
| Total Debt | 0 | 480K | 349K | 532K | 541K |
| Net Debt | (46.92M) | (43.11M) | (92.76M) | (86.7M) | (35.14M) |
Climb Bio, Inc.
NASDAQ:CLYM
Intrinsic Alpha fair value
Locked
Current Price
$9.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.